Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 134

Results For "Risk"

1407 News Found

WHO new Essential Medicines Lists focus on diabetes and cancer
Public Health | September 30, 2021

WHO new Essential Medicines Lists focus on diabetes and cancer

The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all


Glenmark receives marketing approval for Ryaltris in 13 countries across the EU and UK
Drug Approval | September 30, 2021

Glenmark receives marketing approval for Ryaltris in 13 countries across the EU and UK

Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis


Apollo Hospitals dedicates AI tool to predict cardiovascular disease to the nation
Hospitals | September 29, 2021

Apollo Hospitals dedicates AI tool to predict cardiovascular disease to the nation

Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age


Fortis Hospital conducts complex surgery to save a patient with recurrent heart failure
Hospitals | September 29, 2021

Fortis Hospital conducts complex surgery to save a patient with recurrent heart failure

A team of experts at Fortis Gurugram conducted 3-dimensional mapping with the help of the new system Carto version 7 to precisely map the source of the arrhythmia. It was detected that the arrhythmia was coming from the conduction system i.e. body’s natural wiring.


Zebra Medical Vision receives clearance for Coronary Artery Calcium (CAC) solution
Digitisation | September 28, 2021

Zebra Medical Vision receives clearance for Coronary Artery Calcium (CAC) solution

The CAC solution cleared by the U.S. FDA analyses already existing non-gated CT scans and quantifies the coronary artery calcium in order to identify, stratify, and facilitate treatment pathways for patients with cardiovascular disease


SpeeDx and SynGenis partner for custom oligonucleotide synthesis
Supply Chain | September 28, 2021

SpeeDx and SynGenis partner for custom oligonucleotide synthesis

The investment will increase SpeeDx internal capacity to scale up manufacturing


U.S. FDA approves Repatha for paediatric patients aged 10 years and older
Drug Approval | September 27, 2021

U.S. FDA approves Repatha for paediatric patients aged 10 years and older

The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients


SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment
Biotech | September 26, 2021

SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment

Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors


Health Sensei wins Stanford Seed Spark competition
Startup | September 24, 2021

Health Sensei wins Stanford Seed Spark competition

Seed Spark is an online entrepreneurship program offered by Stanford Seed. Health Sensei emerged as a winner competing with 86 startups from their May-Aug 2021 graduating cohort


Pfizer and BioNTech receive U.S. FDA EUA for Covid-19 booster
Drug Approval | September 23, 2021

Pfizer and BioNTech receive U.S. FDA EUA for Covid-19 booster

Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups